ArticleCancer medicine2023

Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study.

Ya Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.